Kiwa Bio-Tech Products Group Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes bio-technological products for the agricultural market primarily in the People’s Republic of China.
Kiwa Bio-Tech Products Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.0051|
|52 Week High||US$0.0031|
|52 Week Low||US$0.09|
|1 Month Change||-34.62%|
|3 Month Change||-57.50%|
|1 Year Change||-16.39%|
|3 Year Change||-99.32%|
|5 Year Change||-99.64%|
|Change since IPO||-99.87%|
Recent News & Updates
|KWBT||US Biotechs||US Market|
Return vs Industry: KWBT underperformed the US Biotechs industry which returned 23.8% over the past year.
Return vs Market: KWBT underperformed the US Market which returned 32.8% over the past year.
Stable Share Price: KWBT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: KWBT's weekly volatility has decreased from 40% to 23% over the past year, but is still higher than 75% of US stocks.
About the Company
Kiwa Bio-Tech Products Group Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes bio-technological products for the agricultural market primarily in the People’s Republic of China. It offers bacillus species and/or photosynthetic bacteria based biological organic, compound microbial, bio-water soluble, and microbial inoculum fertilizers. The company has a strategic cooperation agreements with the Beijing Zhongpin Agricultural Science and Technology Development Center; China Academy of Agricultural Science’s Institute of Agricultural Resources & Regional Planning; and Institute of Agricultural Economy & Development, as well as Kiwa Bio-Tech (Yangling) Co. Ltd.
Kiwa Bio-Tech Products Group Fundamentals Summary
|KWBT fundamental statistics|
Is KWBT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KWBT income statement (TTM)|
|Cost of Revenue||US$30.76m|
Last Reported Earnings
Dec 31, 2019
Next Earnings Date
|Earnings per share (EPS)||0|
|Net Profit Margin||0.00%|
How did KWBT perform over the long term?See historical performance and comparison
Is Kiwa Bio-Tech Products Group undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Kiwa Bio-Tech Products Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Kiwa Bio-Tech Products Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Kiwa Bio-Tech Products Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kiwa Bio-Tech Products Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Kiwa Bio-Tech Products Group performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Kiwa Bio-Tech Products Group has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
How is Kiwa Bio-Tech Products Group's financial position?
Financial Position Analysis
Short Term Liabilities: Insufficient data to determine if KWBT's short term assets cover its short term liabilities.
Long Term Liabilities: Insufficient data to determine if KWBT's short term assets cover its long term liabilities.
Debt to Equity History and Analysis
Debt Level: Insufficient data to calculate KWBT's debt to equity ratio to determine if it is satisfactory.
Reducing Debt: Insufficient data to determine if KWBT's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if KWBT's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if KWBT's interest payments on its debt are well covered by EBIT.
What is Kiwa Bio-Tech Products Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KWBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KWBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KWBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KWBT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KWBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wade Li (60 yo)
Mr. Wade Li serves as Chief Executive Officer at Kiwa Bio-Tech Products Group Corporation since March 04, 2020 and serves as its President since 2020. Mr. Li serves as Chairman at Kiwa Bio-Tech Products Gr...
Experienced Management: KWBT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: KWBT's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.5%.
Kiwa Bio-Tech Products Group Corporation's employee growth, exchange listings and data sources
- Name: Kiwa Bio-Tech Products Group Corporation
- Ticker: KWBT
- Exchange: OTCPK
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.146m
- Shares outstanding: 616.83m
- Website: https://www.kiwabiotech.com
Number of Employees
- Kiwa Bio-Tech Products Group Corporation
- International Agriculture Innovation Hub
- 9th Floor,Yangling Avenue South
- Shaanxi Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 23:01|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.